EM1-7M
PFIZi002-A
General#
Cell Line |
|
| hPSCreg Name | PFIZi002-A |
| Alternative name(s) |
EM1-7M
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 8th December 2017 |
| User feedback | |
Provider |
|
| Generator | Pfizer Limited - Pfizer (PFIZ) |
External Databases |
|
| Cellosaurus | CVCL_9S32 |
General Information |
|
| Publications | |
| Is the cell line available in principle? |
Yes |
Donor Information#
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
Ethics#
We are currently revising this section.hIPSC Derivation#
General |
|
| Source cell type |
erythroblastA nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
|
| Source cell origin |
bloodA fluid that is composed of blood plasma and erythrocytes.
Synonyms
|
| Passage number reprogrammed | 10 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | morphology, pluripotency gene expression, differentiation into sensory neurons |
| Derived under xeno-free conditions |
Unkown |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Dispase
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.